WO2008001968A1 - Antiviral composition comprising alnus pendula extracts - Google Patents

Antiviral composition comprising alnus pendula extracts Download PDF

Info

Publication number
WO2008001968A1
WO2008001968A1 PCT/KR2006/002638 KR2006002638W WO2008001968A1 WO 2008001968 A1 WO2008001968 A1 WO 2008001968A1 KR 2006002638 W KR2006002638 W KR 2006002638W WO 2008001968 A1 WO2008001968 A1 WO 2008001968A1
Authority
WO
WIPO (PCT)
Prior art keywords
influenza virus
extracts
virus
pendula
alnus
Prior art date
Application number
PCT/KR2006/002638
Other languages
French (fr)
Inventor
Hyuk Joon Kwon
Sun Hee Cho
Sun Joong Kim
Young Jin Ahn
Jeong Chan Ra
Original Assignee
Rnl Bio Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rnl Bio Co., Ltd filed Critical Rnl Bio Co., Ltd
Publication of WO2008001968A1 publication Critical patent/WO2008001968A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives

Definitions

  • Antiviral Composition Comprising ⁇ lnus pendula Extracts
  • the present invention relates to an antiviral composition comprising Alnus pendula extracts, more specifically, relates to a composition for preventing or treating diseases caused by influenza virus which infects human, pig, horse, bird, and the like.
  • Viruses cause various diseases, particularly, a typical one among pathogenic viruses that become a problem in the field of stockbreeding is avian influenza virus.
  • Avian influenza virus belongs to the orthomixoviridae family, and cause damage to poultry such as chicken, turkey.
  • Avian influenza virus is classified into 3 types of high- pathogenic, low-pathogenic and non-pathogenic avian influenza viruses according to the degree of pathogenicity, among which the high-pathogenic is classified into "grad A" in the World Organization for Animal Health (OIE) and "the first level domestic animal infectious disease” in Republic of Korea.
  • OIE World Organization for Animal Health
  • the influenza virus is classified into type A, B or C according to the antigenicity of nucleocapsid protein and matrix protein. Moreover, according to the difference of antigen structure of haemagglutinin (HA) and neuraminidase (NA), the HA is classified into 16 subtypes and NA is classified 9 subtypes, wherein HA helps host cell receptor binding, and fusion between host cell membrane and viral envelope to cause a virus infection and NA plays an important role when virus buds out through the cell membrane after proliferation. Theoretically, 144 kinds of virus subtypes could exist by the combination of two proteins. Infection generally occurrs by contact with bird secretions, furthermore, it is spread through the air, in both particle and droplet forms, human feet, vehicle delivering feedstuff, apparatus and feces on the surface of eggs etc.
  • HA haemagglutinin
  • NA neuraminidase
  • infecting virus Although there are various symptoms according to the pathogenicity of infecting virus, generally, they are respiratory symptoms, diarrhea and a sharp decline in egg production ratio etc. Moreover, in some cases, cyanosis appears at the head region such as crest, edema appears on the face, or feathers are ruffled. Mortality rate also varies from 0% to 100% according to pathogenicity, but since the symptoms are similar to those of Newcastle Disease, infectious larynogotracheitis, mycoplasma infection and the like, an accurate diagnosis is required.
  • High-pathogenic avian influenza had occurred 23 times from 1959 to 2003 throughout the world, most of them were endemic and contained. Outbreaks of H5N1 subtype high-pathogenic avian influenza had occurred in Korea in December 2003 occurred in more than 30 countries including Europe, Africa and most countries in Southeast Asia such as Japan, China, Thailand, Vietnam and Indonesia, thus becoming pandemic. Though it is known that human cannot get infected with avian influenza, prevention of avian influenza is being of paramount importance to public health sector due to the case of human infection with H5N1 in 1997, isolation of H9N2 avian influenza viruses from humans in 1999 in Hongkong and human cases of H7 avian influenza infection in 2004 in Canada. According to a report of the World Health Organization (WHO),
  • Natural substances mean, which is not added with artificial factors, and the natural substances classified as GRAS (Generally Recognized As Safe) can be used without restrictions on the quantity thereof or foods in which natural substances are to be used.
  • GRAS Generally Recognized As Safe
  • the natural substances are classified as natural additives, to be used as food additives, and in foreign countries, it has been used as health foods and medical supplies without extra limitation for user's purpose, because of its excellent functionality.
  • Alnus pendula is a dicotyledon plant and a small tree classified in the division order Fagales, family Betulaceae. Its original home is Japan. Its height is 6m ⁇ 8m and fluff of small branch disappears as it grows.
  • the leaf of Alnus pendula grows alternatively and it is long oval shaped and lanceolate. Leaf margin is irregularly saw-toothed. The leaf has 16 ⁇ 27 pairs of veins.
  • the flower of Alnus pendula blooms in April prior to leaf emergence and it is monoecious.
  • the staminate spike droops and pistillate spike extends straight. 3 ⁇ 6 racemes of flowers appear.
  • the flower comprises four stamens, four perianthes and two pistils.
  • the present inventors have made an extensive effort to develop a natural substance having a low toxicity to normal cells, while having an excellent effect to inhibit proliferation of influenza virus. As a result, they found that a composition comprising Alnus pendula extracts have an anti-influenza virus effect, thereby completing the present invention.
  • Main object of the present invention is to provide a food composition for preventing or treating influenza viral diseases comprising the Alnus pendula extracts.
  • Another object of the present invention is to provide a pharmaceutical composition for preventing or treating influenza viral diseases comprising the Alnus pendula extracts.
  • the present invention provides a food composition for preventing or treating influenza viral diseases belonging to the orthomixoviridae family, comprising the Alnus pendula extracts and a sitologically acceptable supplemental additive
  • the present invention also provides a pharmaceutical composition for preventing or treating the influenza virus diseases belonging to the orthomixoviridae family, comprising Alnus pendula extracts as an active ingredient.
  • said influenza virus is preferably selected from the group consisting of: human influenza virus, swine influenza virus, equine influenza virus, and avian influenza virus. More preferably, said avian influenza virus is KBNP-0028 (KCTC 10866BP).
  • the leaves and stems (bark) of Alnus pendula were picked, dried at room temperature for 24 hrs, chopped up and crushed.
  • the obtained powder was added with 99.9% methanol, stirred for 24hrs at room temperature to extract and vacuum-filtered to collect supernatant liquid, followed by eluting useful components from the obtained powder.
  • the useful components are dried for 24hrs at room temperature, and dissolved in 99.9% dimethyl sulfoxide (DMSO) solution to 20 mg/ml, thus preparing Alnus pendula extracts.
  • DMSO dimethyl sulfoxide
  • Alnus pendula extracts of according to the present invention could be obtained by the above described method, those distributed from The Korea Plant Extract Bank were used.
  • Example 2 Examination of anti-viral effect of Alnus pendula extracts 2-1: Preparation of KBNP-0028
  • Veterinary Research and Quarantine Service is low-pathogenic avian influenza virus of H9N2 subtype, isolated from chicken showing mortality and egg drop syndrome. The virus was isolated in a chicken farm located in North jeola City in January 28, 2000.
  • the isolation method is as follows: after kidney and tracheal sample from infected chicken are dissolved, suspended in phosphate buffer, and filterated with 0.45/M diameter filter paper, each sample is inoculated into three allantoic cavities of SPF (Specific Pathogen Free) embryonated egg (Sunrise Co., NY), and cultured at 37 ° C to obtain allantoic fluid.
  • SPF Specific Pathogen Free embryonated egg
  • the 20 ⁇ i of allantoic fluid and 20/z# of 0.1% chicken red blood cells, extracted from a chicken obtained after hatching the SPF embryonated egg, are dropped on glass plate, and mixed to carry out plate hemagglutination test.
  • all of the allantoic fluids obtained by inoculating kidney sample and tracheal sample, formed the hemagglutination.
  • the virus was identified with RT- PCR and the analysis of base sequence using H9N2 specific primer (Kim Min Chul, Master's Thesis, 2002, Seoul National University), and stored at -70 ° C . Among them, the virus isolated from tracheal sample was used in the experiment.
  • the SNU0028 was diluted with phosphate buffer to the concentration of 0.05 to 0.5 HAU/ml. 200//£ of the diluted solution was inoculated into 10- 11 -day-old SPF hatchery egg (Sunrise Co., NY) via the allantoic cavity, and the egg was cultured for three days at 37 °C . Everyday, the embryonated eggs, which died three days ago, was discarded through egg examination in the morming and afternoon. The embryonated eggs, which survived for three days, were stored for 12-24 hrs at 4°C , from which allantoic fluid was collected to measure each of volumn and hemagglutination titer thereof.
  • allantoic fluid having the most quantity and the highest hemagglutination titer was inoculated into embryonated eggs using the same method as described above, and the eggs were subcultured 19 times to eggs whose productivity was increased due to high hemagglutination titer and high yield of allantoic fluid and thus they are named KBNP-0028. It was deposited at GenBank located Eoeundong, Youseonggu, Daejeon city, Korea on October 26, 2005 (KCTC 10866BP).
  • the egg shell of 10 — 11 day-old SPF hatchery egg (Sunrise Co., NY) was washed with 70% ethanol, and all of the chick embryo and body fluid were removed.
  • the resulting egg shell is cut into about 8mm long and 8mm wide while maintaing villi, allantois adhered to the inner surface of egg shell, and put them in a 24-well culture plate piece by piece.
  • the culture medium was prepared by (i) mixing 199 medium (GIBCO-BRL, NY, USA) with FlO medium (GIBCO-BRL, NY, USA) at a ratio of 1 :1, (ii) adding 0.075% of sodium bicarbonate and 100//g/m£ of gentamicin.
  • Culture broth of said virus-infected fluid containing Alnus pendula extracts at each concentration, prepared in Example 2-2 was taken to carry out plate hemagglutination test. 25 ⁇ JL of the culture broth and 25 ⁇ Ji of chicken red blood cells (0.1%) were dropped on glass plate in the same amount and mixed evenly. The virus proliferation was examined according to whether hemagglutination was formed within 2min after moving the glass plate right and left, and up and down. As a result, as shown in Table 1, in the case of leaves, all groups having the concentrations of 100, 200, 300 and 400 showed no antiviral effect and relative cell toxicity.
  • stems (bark)
  • perfect antiviral effect was shown at the concentration of 300 ⁇ g/m#
  • partial antiviral effect was shown at the concentration of 200 ⁇ g/m# (Table 1). Therefore it was concluded that stem (bark) was the most proper material as an antiviral agent.
  • Alnus pendula extracts prepared in example 2-2 was put into 6 well plates of 400, 300, 200 and 100/zgM added with AQ ⁇ Jt of MTT solution (MTT 0.5% aqueous solution), respectively and cultured for 1 ⁇ 3 hrs at 37 ° C . ⁇ 20 ⁇ i of DMSO was added and stirred for 30 min, then the result was read at 562nm wavelength with ELISA (Table 1). As a result, as shown in Table 1, in the case of stems (bark), it was confirmed that the measured value is similar to or higher than the MTT value of the control group added only with virus (0.381 ⁇ 0.057), thus there was no cytotoxicity by extracts.
  • the Alnus pendula extracts according to the present invention have a low toxicity in choriollantonic cell which is a normal cell, while having excellent antiviral effect. Therefore, the composition comprising Alnus pendula extracts can be used effectively in food and pharmaceutical composition since it is effective and safe in preventing and treating influenza virus diseases.

Abstract

The present invention relates to an antiviral composition comprising Alnus pendula extracts, more specifically, relates to a composition for preventing or treating diseases caused by influenza virus which infects human, pig, horse, bird, and the like. The Alnus pendula extracts according to the present invention have a low toxicity in normal cells, while having an excellent antiviral effect and thus the composition comprising Alnus pendula extracts is effectively used in foods and pharmaceutical composition for preventing and treating influenza virus diseases.

Description

Antiviral Composition Comprising Λlnus pendula Extracts
TECHNICAL FIELD
The present invention relates to an antiviral composition comprising Alnus pendula extracts, more specifically, relates to a composition for preventing or treating diseases caused by influenza virus which infects human, pig, horse, bird, and the like.
BACKGROUND ART
Viruses cause various diseases, particularly, a typical one among pathogenic viruses that become a problem in the field of stockbreeding is avian influenza virus. Avian influenza virus belongs to the orthomixoviridae family, and cause damage to poultry such as chicken, turkey. Avian influenza virus is classified into 3 types of high- pathogenic, low-pathogenic and non-pathogenic avian influenza viruses according to the degree of pathogenicity, among which the high-pathogenic is classified into "grad A" in the World Organization for Animal Health (OIE) and "the first level domestic animal infectious disease" in Republic of Korea.
The influenza virus is classified into type A, B or C according to the antigenicity of nucleocapsid protein and matrix protein. Moreover, according to the difference of antigen structure of haemagglutinin (HA) and neuraminidase (NA), the HA is classified into 16 subtypes and NA is classified 9 subtypes, wherein HA helps host cell receptor binding, and fusion between host cell membrane and viral envelope to cause a virus infection and NA plays an important role when virus buds out through the cell membrane after proliferation. Theoretically, 144 kinds of virus subtypes could exist by the combination of two proteins. Infection generally occurrs by contact with bird secretions, furthermore, it is spread through the air, in both particle and droplet forms, human feet, vehicle delivering feedstuff, apparatus and feces on the surface of eggs etc.
Although there are various symptoms according to the pathogenicity of infecting virus, generally, they are respiratory symptoms, diarrhea and a sharp decline in egg production ratio etc. Moreover, in some cases, cyanosis appears at the head region such as crest, edema appears on the face, or feathers are ruffled. Mortality rate also varies from 0% to 100% according to pathogenicity, but since the symptoms are similar to those of Newcastle Disease, infectious larynogotracheitis, mycoplasma infection and the like, an accurate diagnosis is required.
High-pathogenic avian influenza had occurred 23 times from 1959 to 2003 throughout the world, most of them were endemic and contained. Outbreaks of H5N1 subtype high-pathogenic avian influenza had occurred in Korea in December 2003 occurred in more than 30 countries including Europe, Africa and most countries in Southeast Asia such as Japan, China, Thailand, Vietnam and Indonesia, thus becoming pandemic. Though it is known that human cannot get infected with avian influenza, prevention of avian influenza is being of paramount importance to public health sector due to the case of human infection with H5N1 in 1997, isolation of H9N2 avian influenza viruses from humans in 1999 in Hongkong and human cases of H7 avian influenza infection in 2004 in Canada. According to a report of the World Health Organization (WHO),
(http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_06_20/en /index.html), it was confirmed that the 228 persons were infected with H5N1 subtype and 130 persons of them died during the period of 2003 to June 20, 2006 in 10 countries. In Korea, since low-pathogenic avian influenza by H9N2 subtype had occurred in 1996, it reoccurred in 1999 and now it has been occurring throughout the whole country.
If avian influenza occurs, in most countries, poultry were slaughtered, and countries which have confirmed outbreaks of avian influenza cannot export poultry products to cause swingeing damages into poultry industry. Furthermore, when there is a risk of human infection, the damages spread to the whole industry including the tourist industry and the transport industry, thus causing astronomical loss including.
Natural substances mean, which is not added with artificial factors, and the natural substances classified as GRAS (Generally Recognized As Safe) can be used without restrictions on the quantity thereof or foods in which natural substances are to be used. In domestic industry, the natural substances are classified as natural additives, to be used as food additives, and in foreign countries, it has been used as health foods and medical supplies without extra limitation for user's purpose, because of its excellent functionality.
Meanwhile, Alnus pendula is a dicotyledon plant and a small tree classified in the division order Fagales, family Betulaceae. Its original home is Japan. Its height is 6m~8m and fluff of small branch disappears as it grows. The leaf of Alnus pendula grows alternatively and it is long oval shaped and lanceolate. Leaf margin is irregularly saw-toothed. The leaf has 16~27 pairs of veins.
The flower of Alnus pendula blooms in April prior to leaf emergence and it is monoecious. The staminate spike droops and pistillate spike extends straight. 3~6 racemes of flowers appear. The flower comprises four stamens, four perianthes and two pistils.
Recently, many researchers endeavor to develop anti-viral agents throughout the world. Lamibudine used for the treatment of HIV (Human Immunodeficiency Virus)- 1 and hepatitis B, gancyclovir used for the treatment of symptoms of herpes virus infection, ribavirin which is used mainly for the treatment of symptoms of respiratory syncytial virus infection but can be used for the treatment of symptoms of various virus infection when it is an emergency and zanamivir RELENZA™ and oseltamivir, TAMIFLU™ which are synthesized artificially as neuraminidase inhibitors of influenza virus are all commercially available after getting approval. However, use of amantadine and its analogue, rimantadine, which are approved for treatment of influenza virus A has decreased for the appearance of resistant virus and its side effect. Recently, virus resistant to oseltamivir among H5N1 avian influenza viruses appeared, therefore, developments of various anti- virus agents are urgently required.
Therefore, the present inventors have made an extensive effort to develop a natural substance having a low toxicity to normal cells, while having an excellent effect to inhibit proliferation of influenza virus. As a result, they found that a composition comprising Alnus pendula extracts have an anti-influenza virus effect, thereby completing the present invention.
DETAILED DESCRIPTION OF THE INVENTION, AND
PREFERRED EMBODIMENTS
Main object of the present invention is to provide a food composition for preventing or treating influenza viral diseases comprising the Alnus pendula extracts.
Another object of the present invention is to provide a pharmaceutical composition for preventing or treating influenza viral diseases comprising the Alnus pendula extracts.
To achieve the above object, the present invention provides a food composition for preventing or treating influenza viral diseases belonging to the orthomixoviridae family, comprising the Alnus pendula extracts and a sitologically acceptable supplemental additive
The present invention also provides a pharmaceutical composition for preventing or treating the influenza virus diseases belonging to the orthomixoviridae family, comprising Alnus pendula extracts as an active ingredient.
In the present invention, said influenza virus is preferably selected from the group consisting of: human influenza virus, swine influenza virus, equine influenza virus, and avian influenza virus. More preferably, said avian influenza virus is KBNP-0028 (KCTC 10866BP).
Examples
Hereinafter, the present invention will be described in more detail by examples.
However, it is obvious to a person skilled in the art that these examples are for illustrative purpose only and are not construed to limit the scope of the present invention.
Example 1: Preparation of Alnus pendula extracts
The leaves and stems (bark) of Alnus pendula were picked, dried at room temperature for 24 hrs, chopped up and crushed. The obtained powder was added with 99.9% methanol, stirred for 24hrs at room temperature to extract and vacuum-filtered to collect supernatant liquid, followed by eluting useful components from the obtained powder. The useful components are dried for 24hrs at room temperature, and dissolved in 99.9% dimethyl sulfoxide (DMSO) solution to 20 mg/ml, thus preparing Alnus pendula extracts.
Although the Alnus pendula extracts of according to the present invention could be obtained by the above described method, those distributed from The Korea Plant Extract Bank were used.
Example 2: Examination of anti-viral effect of Alnus pendula extracts 2-1: Preparation of KBNP-0028
As avian influenza virus used in the experiment, hyperproliferative KBNP-0028 (KR
2006-0026591) cloned after subculturing A/chicken/Korea/SNU0028/2000 (H9N2) virus (it is isolated in Korea in 2000) in chick embryo was used. That is, SNU0028
[A/chicken/Korea/SNU0028/2000 (H9N2); isolation and report to National
Veterinary Research and Quarantine Service, May 9, 2005] is low-pathogenic avian influenza virus of H9N2 subtype, isolated from chicken showing mortality and egg drop syndrome. The virus was isolated in a chicken farm located in North jeola Province in January 28, 2000.
The isolation method is as follows: after kidney and tracheal sample from infected chicken are dissolved, suspended in phosphate buffer, and filterated with 0.45/M diameter filter paper, each sample is inoculated into three allantoic cavities of SPF (Specific Pathogen Free) embryonated egg (Sunrise Co., NY), and cultured at 37 °C to obtain allantoic fluid. The 20 μi of allantoic fluid and 20/z# of 0.1% chicken red blood cells, extracted from a chicken obtained after hatching the SPF embryonated egg, are dropped on glass plate, and mixed to carry out plate hemagglutination test.
As a result, all of the allantoic fluids, obtained by inoculating kidney sample and tracheal sample, formed the hemagglutination. The virus was identified with RT- PCR and the analysis of base sequence using H9N2 specific primer (Kim Min Chul, Master's Thesis, 2002, Seoul National University), and stored at -70 °C . Among them, the virus isolated from tracheal sample was used in the experiment.
In order to select a vaccinia strain having high productivity of embryonated egg, the SNU0028 was diluted with phosphate buffer to the concentration of 0.05 to 0.5 HAU/ml. 200//£ of the diluted solution was inoculated into 10- 11 -day-old SPF hatchery egg (Sunrise Co., NY) via the allantoic cavity, and the egg was cultured for three days at 37 °C . Everyday, the embryonated eggs, which died three days ago, was discarded through egg examination in the morming and afternoon. The embryonated eggs, which survived for three days, were stored for 12-24 hrs at 4°C , from which allantoic fluid was collected to measure each of volumn and hemagglutination titer thereof. Among them, allantoic fluid having the most quantity and the highest hemagglutination titer was inoculated into embryonated eggs using the same method as described above, and the eggs were subcultured 19 times to eggs whose productivity was increased due to high hemagglutination titer and high yield of allantoic fluid and thus they are named KBNP-0028. It was deposited at GenBank located Eoeundong, Youseonggu, Daejeon city, Korea on October 26, 2005 (KCTC 10866BP).
2-2: Culturing hatchery egg shell fragments
The egg shell of 10 — 11 day-old SPF hatchery egg (Sunrise Co., NY) was washed with 70% ethanol, and all of the chick embryo and body fluid were removed. The resulting egg shell is cut into about 8mm long and 8mm wide while maintaing villi, allantois adhered to the inner surface of egg shell, and put them in a 24-well culture plate piece by piece. The culture medium was prepared by (i) mixing 199 medium (GIBCO-BRL, NY, USA) with FlO medium (GIBCO-BRL, NY, USA) at a ratio of 1 :1, (ii) adding 0.075% of sodium bicarbonate and 100//g/m£ of gentamicin.
To the 10 — 11 -day-old SPF embryonated egg (Sunrise Co., NY) was infected with virus by adding 100 μl of crude allantoic fluid KBNP-0028 prepared in Example 2-1, which is 4~10-fold diluted to the surface of villi, allantois of hatchery egg shell fragments, and culturing for 30 min at 37 °C . After adding lOOOμβ of the culture medium, Alnus pendula extracts was added to 6 well plates, respectively to the concentration of 400, 300, 200 and 100μg/m£. The virus-infected fluid containing Alnus pendula extracts was cultured for 7 days at 37°C . 2-3: Test of antiviral effect
Culture broth of said virus-infected fluid containing Alnus pendula extracts at each concentration, prepared in Example 2-2 was taken to carry out plate hemagglutination test. 25 μJL of the culture broth and 25μJi of chicken red blood cells (0.1%) were dropped on glass plate in the same amount and mixed evenly. The virus proliferation was examined according to whether hemagglutination was formed within 2min after moving the glass plate right and left, and up and down. As a result, as shown in Table 1, in the case of leaves, all groups having the concentrations of 100, 200, 300 and 400 showed no antiviral effect and relative cell toxicity. In the case of stems (bark), perfect antiviral effect was shown at the concentration of 300μg/m#, and partial antiviral effect was shown at the concentration of 200μg/m# (Table 1). Therefore it was concluded that stem (bark) was the most proper material as an antiviral agent.
2-4: MTT assay
Alnus pendula extracts prepared in example 2-2 was put into 6 well plates of 400, 300, 200 and 100/zgM added with AQμJt of MTT solution (MTT 0.5% aqueous solution), respectively and cultured for 1~3 hrs at 37°C . \20μi of DMSO was added and stirred for 30 min, then the result was read at 562nm wavelength with ELISA (Table 1). As a result, as shown in Table 1, in the case of stems (bark), it was confirmed that the measured value is similar to or higher than the MTT value of the control group added only with virus (0.381±0.057), thus there was no cytotoxicity by extracts. However, in the case of leaves, the measured value is relatively lower than the MTT value of the control group, therefore it was concluded that stem (bark) is the most proper material as an antiviral agent. Table 1: MTT Assay result according to the part of Alnus pendula
Figure imgf000010_0001
INDUSTRIAL APPLICABILITY
As described above in detail, the Alnus pendula extracts according to the present invention have a low toxicity in choriollantonic cell which is a normal cell, while having excellent antiviral effect. Therefore, the composition comprising Alnus pendula extracts can be used effectively in food and pharmaceutical composition since it is effective and safe in preventing and treating influenza virus diseases.
Although the present invention has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only for a preferred embodiment and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

Claims

THE CLAIMS
What is Claimed is:
L A composition of foods for preventing or treating influenza virus diseases, comprising Alnus pendula extracts and a sitologically acceptable supplemental additive.
2. The composition according to claim 1, wherein said influenza virus is any one selected from the group consisting of: human influenza virus, swine influenza virus, equine influenza virus, and avian influenza virus.
3. The composition according to claim 2, wherein said avian influenza virus is KBNP-0028 (KCTC 10866BP)
4. A pharmaceutical composition for preventing or treating influenza virus diseases, comprising Alnus pendula extracts as an active ingredient.
5. The pharmaceutical composition according to claim 4, wherein said influenza virus is any one selected from the group consisting of: human influenza virus, swine influenza virus, equine influenza virus, and avian influenza virus
6. The pharmaceutical composition according to claim 5, wherein said avian influenza virus is KBNP-0028 (KCTC 10866BP).
PCT/KR2006/002638 2006-06-29 2006-07-06 Antiviral composition comprising alnus pendula extracts WO2008001968A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2006-0059191 2006-06-29
KR1020060059191A KR100757712B1 (en) 2006-06-29 2006-06-29 Antiviral composition comprising alnus pendula extracts

Publications (1)

Publication Number Publication Date
WO2008001968A1 true WO2008001968A1 (en) 2008-01-03

Family

ID=38737403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2006/002638 WO2008001968A1 (en) 2006-06-29 2006-07-06 Antiviral composition comprising alnus pendula extracts

Country Status (2)

Country Link
KR (1) KR100757712B1 (en)
WO (1) WO2008001968A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005010A1 (en) * 2008-07-09 2010-01-14 有限会社生物資源研究所 Anti-influenza virus agent, anti-rs virus agent, and anti-immunodeficiency virus agent
DE102011117607A1 (en) 2011-10-28 2013-05-02 Highyag Lasertechnologie Gmbh Optical system useful e.g. for imaging laser beam, comprises collimating objective, in which first- and third lens group have positive focal length, and second lens group has negative focal length, beam source, and focusing-objective

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0182244B1 (en) * 1997-04-21 1999-05-01 최승주 Pharmaceutical preparations having anticancer activity which include a diaryl heptanoid derivative as an active ingredient
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
JP2003300860A (en) * 2002-02-05 2003-10-21 Kose Corp Skin care preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0182244B1 (en) * 1997-04-21 1999-05-01 최승주 Pharmaceutical preparations having anticancer activity which include a diaryl heptanoid derivative as an active ingredient
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
JP2003300860A (en) * 2002-02-05 2003-10-21 Kose Corp Skin care preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TAKAYUKI SUGA ET AL.: "A C31-secodammarane-type triterpenic acid, 12-deoxy alnustic acid, from the female flowers of alnus pendula", PHYTOCHEMISTRY, vol. 25, no. 5, 23 April 1986 (1986-04-23), pages 1243 - 1244 *
TAKAYUKI SUGA ET AL.: "C31,-secodammarane-type triterpenoid saponins from the male flowers of Alnus pendula", PHYTOCHEMISTRY, vol. 23, no. 6, 14 May 1984 (1984-05-14), pages 1297 - 1299 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005010A1 (en) * 2008-07-09 2010-01-14 有限会社生物資源研究所 Anti-influenza virus agent, anti-rs virus agent, and anti-immunodeficiency virus agent
JPWO2010005010A1 (en) * 2008-07-09 2012-01-05 有限会社生物資源研究所 Anti-influenza virus agent, anti-RS virus agent and anti-immunodeficiency virus agent
DE102011117607A1 (en) 2011-10-28 2013-05-02 Highyag Lasertechnologie Gmbh Optical system useful e.g. for imaging laser beam, comprises collimating objective, in which first- and third lens group have positive focal length, and second lens group has negative focal length, beam source, and focusing-objective

Also Published As

Publication number Publication date
KR100757712B1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
US20100189827A1 (en) Antiviral composition comprising alnus japonica extracts
KR101317318B1 (en) A composition comprising the extract of Galla Rhois or the compounds isolated therefrom showing inhibiting activity of novel influenza, avian influenza, or SARS syndrome
US8470378B2 (en) Anti-influenza viral composition containing bark or stem extract of Alnus japonica
CN101873861A (en) The composition for preventing virus infection that contains poly-gamma-glutamic acid
KR100769050B1 (en) Antiviral composition comprising alnus japonic extracts
KR100743861B1 (en) Composition comprising an extract of Pine needle for preventing and treating human disease caused by viruses
WO2007046643A1 (en) Composition comprising an extract of pine needle for preventing and treating animal disease caused by viruses and the use thereof
CN109419786A (en) Purposes of the cannabidiol in the drug of preparation anti influenza
WO2008001968A1 (en) Antiviral composition comprising alnus pendula extracts
US20090175963A1 (en) Antiviral composition comprising lycoris squamigera extracts
KR100740563B1 (en) Antiviral composition comprising lycoris squamigera extracts
JP5713484B2 (en) Composition for prevention and / or treatment of viral infections comprising plant extract, preventive and / or therapeutic agent for viral infections comprising these as active ingredients, and inhibitor of viral adsorption to cells
KR20090097886A (en) Compositions and methods for treating infectious bronchitis
CN102166276B (en) Traditional Chinese medicine composition for preventing and treating influenza A and preparation method and application thereof
KR100762149B1 (en) Antiviral composition comprising acer ginnal extracts
KR100881035B1 (en) Composition comprising an extract of Celosia for preventing and treating human disease caused by viruses
KR100881033B1 (en) Composition comprising an extract of Celosia for preventing and treating animal disease caused by viruses
Sainhi et al. A Review Article on Phytochemicals New Line of Treatment of Sars Covid-19
TWI727638B (en) Use of fucoidan for inhibiting avian influenza virus
KR101135946B1 (en) A theraputic composition containing extracts of Forsythia suspensa Vahl against highly pathogenic avian influenza
KR20100063223A (en) Pharmaceutical composite for the suppression of avian influenza infection by using korean mistletoe
JP2024512559A (en) Spirulina-based compositions and their use for strengthening immunity
KR20230146695A (en) Composition for inhibiting influenza virus
KR20220087654A (en) Antiviral composition containing Mori Ramulus derived compound as an active ingredient
KR100853442B1 (en) The health food for preventing infectious disease by influenza virus comprising cathechin derivative compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06769184

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06-04-2009 )

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSSOF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06-04-2009)

122 Ep: pct application non-entry in european phase

Ref document number: 06769184

Country of ref document: EP

Kind code of ref document: A1